Cargando…
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new anticancer therapies. Historically, however, both genes have proved challenging to target and currently there is no approved therapy against either. The aim of this study was to inves...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447602/ https://www.ncbi.nlm.nih.gov/pubmed/37233863 http://dx.doi.org/10.1007/s10637-023-01368-1 |